January/February

Keep an eye out for these specialty pipeline medications in 2019.

They may still suggest revisions to latest standards but must prepare regardless for new compounding regulations.

Although the leading treatment for hemophilia is a replacement therapy in the form of both plasma-derived and rF products, research is underway for the discovery of novel agents.

It is critical that we continue to recognize that better health outcomes are a critically important corollary to value.

There is no doubt that 2018 was a year of transformation across the health care spectrum, and specialty pharmacy was no exception.

For a current compounder or someone looking to enter the space, it is imperative that their business remains on top of the latest compounding developments.

Through ongoing quarterly targeted medication counseling follow-up sessions, the pharmacist may identify ART noncompliance.

Following a year in which nearly 40 specialty drugs were approved by the FDA, 2019 also is expected to be huge in the specialty market, with more therapies for cancer, multiple sclerosis, and orphan conditions on the horizon.

Not a day goes by without a health care–related headline, and our industry continues to be influenced by change, some positive and some less so.

Navigating insurance coverage for specialty drugs has always been a complex and fundamental part of the specialty drug distribution chain.